UBS Group’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.15M | Buy |
175,182
+92,476
| +112% | +$1.81M | ﹤0.01% | 4643 |
|
|
2026
Q1 | $1.52M | Buy |
82,706
+75,581
| +1,061% | +$868K | ﹤0.01% | 5212 |
|
|
2025
Q4 | $84.5K | Sell |
7,125
-5,536
| -44% | -$70.5K | ﹤0.01% | 6990 |
|
|
2025
Q3 | $151K | Buy |
12,661
+12,438
| +5,578% | +$165K | ﹤0.01% | 6842 |
|
|
2025
Q2 | $3.6K | Sell |
223
-4,436
| -95% | -$93.8K | ﹤0.01% | 9333 |
|
|
2025
Q1 | $97.8K | Buy |
4,659
+2,370
| +104% | +$63.4K | ﹤0.01% | 7064 |
|
|
2024
Q4 | $57K | Buy |
2,289
+1,605
| +235% | +$43.8K | ﹤0.01% | 7218 |
|
|
2024
Q3 | $11.6K | Sell |
684
-146
| -18% | -$3.06K | ﹤0.01% | 7672 |
|
|
2024
Q2 | $23.4K | Buy |
830
+815
| +5,433% | +$84.7K | ﹤0.01% | 7203 |
|
|
2024
Q1 | $4.5K | Buy |
15
+8
| +114% | +$2.39K | ﹤0.01% | 7620 |
|
|
2023
Q4 | $1.61K | Buy |
+7
| New | +$1.09K | ﹤0.01% | 8261 |
|
|
2023
Q3 | – | Sell |
-63
| Closed | -$11K | – | 9638 |
|
|
2023
Q2 | $11K | Sell |
63
-51
| -45% | -$8.55K | ﹤0.01% | 7116 |
|
|
2023
Q1 | $14.4K | Buy |
+114
| New | +$25.7K | ﹤0.01% | 7349 |
|
|
2022
Q4 | – | Sell |
-173
| Closed | -$10K | – | 10867 |
|
|
2022
Q3 | $10K | Buy |
+173
| New | +$12.4K | ﹤0.01% | 8424 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 10547 |
|
|
2022
Q1 | – | Sell |
-211
| Closed | -$24.8K | – | 10488 |
|
|
2021
Q4 | $30K | Buy |
+211
| New | +$38.3K | ﹤0.01% | 7398 |
|
|
2021
Q3 | – | Sell |
-103
| Closed | -$21.8K | – | 9744 |
|
|
2021
Q2 | $24K | Sell |
103
-172
| -63% | -$43.8K | ﹤0.01% | 7141 |
|
|
2021
Q1 | $83K | Sell |
275
-315
| -53% | -$113K | ﹤0.01% | 6108 |
|
|
2020
Q4 | $222K | Buy |
590
+161
| +38% | +$56.4K | ﹤0.01% | 5175 |
|
|
2020
Q3 | $132K | Sell |
429
-113
| -21% | -$43.2K | ﹤0.01% | 5033 |
|
|
2020
Q2 | $204K | Sell |
542
-119
| -18% | -$33.7K | ﹤0.01% | 4784 |
|
|
2020
Q1 | $151K | Sell |
661
-229
| -26% | -$87.5K | ﹤0.01% | 4936 |
|
|
2019
Q4 | $471K | Buy |
890
+462
| +108% | +$250K | ﹤0.01% | 4889 |
|
|
2019
Q3 | $185K | Sell |
428
-123
| -22% | -$79.1K | ﹤0.01% | 5305 |
|
|
2019
Q2 | $656K | Sell |
551
-189
| -26% | -$226K | ﹤0.01% | 4092 |
|
|
2019
Q1 | $922K | Buy |
740
+282
| +62% | +$323K | ﹤0.01% | 3646 |
|
|
2018
Q4 | $434K | Buy |
458
+275
| +150% | +$331K | ﹤0.01% | 4374 |
|
|
2018
Q3 | $263K | Buy |
183
+180
| +6,000% | +$272K | ﹤0.01% | 4848 |
|
|
2018
Q2 | $5K | Sell |
3
-1,251
| -100% | -$2.15M | ﹤0.01% | 7463 |
|
|
2018
Q1 | $2.04M | Buy |
1,254
+1,251
| +41,700% | +$2.6M | ﹤0.01% | 3126 |
|
|
2017
Q4 | $5K | Sell |
3
-20
| -87% | -$26.4K | ﹤0.01% | 7375 |
|
|
2017
Q3 | $32K | Buy |
23
+19
| +475% | +$22.3K | ﹤0.01% | 6113 |
|
|
2017
Q2 | $4K | Sell |
4
-14
| -78% | -$11.6K | ﹤0.01% | 7202 |
|
|
2017
Q1 | $10K | Sell |
18
-13
| -42% | -$7.98K | ﹤0.01% | 6605 |
|
|
2016
Q4 | $19K | Buy |
31
+24
| +343% | +$15K | ﹤0.01% | 6544 |
|
|
2016
Q3 | $5K | Buy |
+7
| New | +$5.36K | ﹤0.01% | 7123 |
|
|
2016
Q2 | – | Sell |
-12
| Closed | -$7K | – | 7815 |
|
|
2016
Q1 | $7K | Buy |
+12
| New | +$6.15K | ﹤0.01% | 6851 |
|
|
2015
Q4 | – | Sell |
-14
| Closed | -$8K | – | 8435 |
|
|
2015
Q3 | $8K | Sell |
14
-6
| -30% | -$4.33K | ﹤0.01% | 7408 |
|
|
2015
Q2 | $16K | Buy |
20
+9
| +82% | +$7.45K | ﹤0.01% | 7074 |
|
|
2015
Q1 | $9K | Buy |
+11
| New | +$8.54K | ﹤0.01% | 7716 |
|
Other funds holding CBIO
FFM
LGM
FIS
BCM
NCM
UBS Group's CBIO Position: Q2 2026 in Review
UBS Group increased its Crescent Biopharma (CBIO) stake by 112% in Q2 2026, buying an estimated $1.81M and bringing the position to 175,182 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4643.
UBS Group first reported a position in CBIO in Q1 2015 and has held it in 39 quarters since. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.
- UBS Group held 175,182 shares of Crescent Biopharma worth $3.15M as of Q2 2026.
- UBS Group bought 92,476 Crescent Biopharma shares in Q2 2026, an estimated $1.81M.
- Crescent Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4643 holding.
- UBS Group first reported a position in Crescent Biopharma in Q1 2015 and has held it in 39 quarters since.
- 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.